Treatment of Pembrolizumab-Induced Mucocutaneous Lichen Planus With Metronidazole

2024-9-18

Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa

2024-9-18

Widespread Micropapular Eruption

2024-9-11

Consensus on a Patient-Centered Definition of Atopic Dermatitis Flare

2024-9-11

Incidence and Prevalence of Morphea

2024-9-11

Cord Blood Serum Levels of IL-31 and CCL17, Cutaneous Markers, and Development of Atopic Dermatitis

2024-9-11

Prescription Cost-Saving Platforms in Dermatology

2024-9-11

Melanoma Incidence and Mortality Trends in Sweden

2024-9-8

Revertant Mosaic Skin Punch Grafting in Recessive Dystrophic Epidermolysis Bullosa

2024-9-4

Orofacial Manifestations of Kindler Epidermolysis Bullosa

2024-9-4

Orofacial Manifestations of Kindler Epidermolysis Bullosa—Reply

2024-9-4

Skin Cancer and Other Dermatologic Conditions Among US Veterans

2024-9-4

Skin Cancer Care in US Veterans—Serving Those Who Served

2024-9-4

Low-Dose Metformin and Profibrotic Signature in Central Centrifugal Cicatricial Alopecia

2024-9-4

Genetic Aspects of Necrobiotic Xanthogranuloma

2024-9-4

JAMA Dermatology

2024-9-1

Error in Studies Included

2024-9-1

Pustular Erythroderma in an Infant

2024-8-28

Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria

2024-8-28

Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis

2024-8-28

CLAPO Syndrome

2024-8-28

Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma—What’s in a Name?—Reply

2024-8-28

Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

2024-8-28

Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma—What’s in a Name?

2024-8-28

Smoking Cessation and Risk of Hidradenitis Suppurativa Development

2024-8-21

Smoking Cessation and Hidradenitis Suppurativa

2024-8-21

Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis

2024-8-21

Cutaneous Collagenous Vasculopathy Associated With Antibody-Drug Conjugate Treatment

2024-8-21

Epidermolysis Bullosa Pruriginosa Treated With Upadacitinib

2024-8-21

Does the Germline Genome Encode for the Invasiveness of a Cutaneous Melanoma?

2024-8-14

Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata

2024-8-14

Characteristics of Hispanic Patients With Dermatomyositis

2024-8-14

Exploring the Germline Genetics of In Situ and Invasive Cutaneous Melanoma

2024-8-14

Linear Depigmentation After Local Corticosteroid Injection

2024-8-14

Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis

2024-8-7

Umbilicated Nodular Ulcerative Lesions in a Patient With Previous Kidney Transplant

2024-8-7

Frequency of Skin Biopsies for Psoriasis by Race and Ethnicity

2024-8-7

Rapid Improvement in Refractory Acute Generalized Exanthematous Pustulosis With Spesolimab

2024-8-7

JAMA Dermatology

2024-8-1

Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis

2024-7-31

Primary Cutaneous Cryptococcosis

2024-7-31

Immune-Mediated and Psychiatric Comorbidities Among Patients Newly Diagnosed With Alopecia Areata

2024-7-31

Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis

2024-7-31

Upadacitinib for Treatment of Granulomatous Cheilitis

2024-7-31

Equipping Dermatologists to Address Structural and Social Drivers of Inequities—Structural Competency

2024-7-31

Advancing Research in Cutaneous Squamous Cell Carcinoma—Precision Management Requires Precision Data

2024-7-24

Exanthematous Eruption in a Patient With Known Chronic Graft-vs-Host Disease and Recent Measles Vaccination

2024-7-24

Error in Table Footnote

2024-7-24

Favorable Response to Type 2 Inhibitors in Patients With Darier Disease

2024-7-24

Area Deprivation and Disease Severity in Adult Patients With Discoid Lupus Erythematosus

2024-7-24